Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00738101 · ClinicalTrials.gov registry record · NA
Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants
A NA study of Cholestasis and Cholestasis of Parenteral Nutrition, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 293
- Enrollment target
- 2
- Study locations
NCT00738101 is a NA study of Cholestasis and Cholestasis of Parenteral Nutrition that has completed, run by Baylor College of Medicine. The registered enrollment target is 293 participants, above the 109-participant average among 6 other Cholestasis trials with a reported enrollment target (169% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT00738101, a NA study of Cholestasis and Cholestasis of Parenteral Nutrition, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 293 participants
- Enrollment target
- 2
- Study locations
Study Summary
To provide a mechanism for critically ill infants with parenteral nutrition (PN) associated cholestasis to receive Omegaven for compassionate use situations for which there are no satisfactory alternative treatments.
Conditions Studied
Interventions
- DRUG Omegaven
Study Locations (2)
Texas
- Baylor College of Medicine - Houston
- Texas Children's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 293 participants |
| Start Date | 2008-09 |
| Est. Completion | 2020-03-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00738101
The ClinicalTrials.gov registry entry for NCT00738101 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 293 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 109-participant average among 6 other Cholestasis trials with a reported enrollment target (169% higher). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cholestasis appearing as the primary indexed condition, and to 1 intervention - of which Omegaven is the first listed.
NCT00738101 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00738101 about?
NCT00738101 is a clinical study titled "Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants". To provide a mechanism for critically ill infants with parenteral nutrition (PN) associated cholestasis to receive Omegaven for compassionate use situations for which there are no satisfactory alternative treatments.
What is the current status of trial NCT00738101?
This trial is currently completed. It is a NA study. The enrollment target is 293 participants. The study started on 2008-09. Estimated completion is 2020-03-27.
What conditions does trial NCT00738101 study?
This clinical trial studies the following conditions: Cholestasis, Cholestasis of Parenteral Nutrition.
What interventions are being tested in trial NCT00738101?
The interventions under investigation include: Omegaven (DRUG).
Who is sponsoring clinical trial NCT00738101?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00738101 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholestasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis
COMPLETED · NA
-
Linerixibat Long-term Safety, and Tolerability Study
ACTIVE NOT RECRUITING · Phase 3
-
Osmotic Fragility in Red Blood Cells of Pediatric Patients With Cholestatic Liver Disease
ACTIVE NOT RECRUITING
-
Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
COMPLETED · Phase 3
-
Gabapentin to Treat Itch in Patients With Liver Disease
COMPLETED · Phase 3
-
Cholestasis Prevention: Efficacy of IV Fish Oil
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.